Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06019559 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833
A Phase 2 study, sponsored by Kallyope.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT06019559: Completed Phase 2 study, sponsored by Kallyope.
NCT06019559 is a Phase 2 study that has completed, run by Kallyope. The registered enrollment target is 155 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06019559, a Phase 2 study, has completed, sponsored by Kallyope.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
This is a study to evaluate the safety and efficacy of K-757 alone and in combination with K-833 versus placebo in participants who are obese.
Interventions
- DRUG Matching placebo to K-757 and matching placebo to K-833
- DRUG K-757 120 mg BID and K-833 100 mg BID
- DRUG K-757 120 mg BID and matching placebo to K-833
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2023-09-15 |
| Est. Completion | 2024-02-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06019559
The ClinicalTrials.gov registry entry for NCT06019559 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kallyope, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Matching placebo to K-757 and matching placebo to K-833 is the first listed.
NCT06019559 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06019559 about?
NCT06019559 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833". This is a study to evaluate the safety and efficacy of K-757 alone and in combination with K-833 versus placebo in participants who are obese.
What is the current status of trial NCT06019559?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2023-09-15. Estimated completion is 2024-02-19.
What interventions are being tested in trial NCT06019559?
The interventions under investigation include: Matching placebo to K-757 and matching placebo to K-833 (DRUG), K-757 120 mg BID and K-833 100 mg BID (DRUG), K-757 120 mg BID and matching placebo to K-833 (DRUG).
Who is sponsoring clinical trial NCT06019559?
This trial is sponsored by Kallyope, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.